Skip Navigation


NDT Advance Access originally published online on April 20, 2006
Nephrology Dialysis Transplantation 2006 21(8):2049-2052; doi:10.1093/ndt/gfl168
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/8/2049    most recent
gfl168v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jacobs, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Costs and benefits of improving renal failure treatment—where do we go?

Claude Jacobs

Service de Néphrologie, Hôpital de la Pitié, Paris, France

Correspondence and offprint requests to: Dr C. Jacobs, Service de Néphrologie, Hôpital de la Pitié, 83, Boulevard de l'Hôpital 75013, Paris, France. Email: claude.jacobs@psl.aphp.fr; claude.jacobs@psl.ap-hop-paris.fr

Keywords: chronic kidney disease; dialysis; economics; nephroprotection

The first 150 words of the full text of this article appear below.

Less than 50 years ago, a therapeutic revolution totally changed the inevitable lethal prognosis of established chronic kidney disease (CKD), as maintenance dialysis methods and renal transplantation (TX) proved the possibility of prolonged survival for patients with end-stage renal failure (ESRF). The first priority of clinical nephrologists in developed countries has, therefore, been the struggle for the widest possible implementation of dialysis and transplant facilities, and the training of medical, nursing and technical staff in these new areas of medical practice. By the end of 2004, close to 1.8 million patients were treated worldwide with renal replacement therapy (RRT), 77% on maintenance dialysis and 23% living with a functional transplant [1]. To date, about 90% of patients benefiting from RRT live in the more developed countries of the Western hemisphere, Japan and Australia, while sadly, more than 5.2 billion people, 82% of the of the total world population, . . . [Full Text of this Article]



   Facing such a complex and hazardous future, can the cost-effectiveness of renal therapy be improved? Definitely YES
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?